IP Library Granted Patent US 8,664,441
Granted Patent B2
US 8,664,441 · App. 13/934,996 · Granted Mar 4, 2014

Acetamide stereoisomer

Inventors: Craig R. Abolin (Boylston, MA); H. Scott Wilkinson (Westborough, MA); Paul McGlynn (Northborough, MA); William K. McVicar (Sudbury, MA)
Assignee: Sunovion Pharmaceuticals Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,664,441
App. No.
13/934,996
Granted
Mar 4, 2014
Kind
B2
Abstract

The compound of formula (I) is a water-stable, long acting β 2 -selective adrenoceptor agonist useful as a bronchodilator in the treatment of bronchoconstriction associated with reversible obstructive airways diseases and the like. Processes for making the compound of formula (I), as well as related intermediates, are disclosed.

Claims (19)

1. A process for the preparation of

which comprises reacting a compound of general formula (II)

in which P 1 represents a hydrogen atom or a hydroxyl protecting group, with a compound of general formula (III)

in which P 2 represents a hydrogen atom or a trialkylsilyl and P 3 represents a benzylic amine protecting group, to afford a compound of general formula (IV)

or a salt thereof, followed by removing any protecting groups P 1 , P 2 and P 3 and, if desired, forming a pharmaceutically acceptable acid addition salt.

2. A process according to claim 1 wherein the trialkylsilyl is TBDMS.

3. A process for the preparation of

which comprises

a) reacting a compound of general formula (VII)

wherein Bn represents benzyl,

with boron tribromide to form a compound of general formula (VIII)

b) reacting said compound of general formula (VIII) with trialkylsilyl halide to form a compound of general formula (III)

in which P 2 represents a trialkylsilyl;

c) reacting said compound of general formula (III) with a compound of general formula (II)

in which P 1 represents a hydrogen atom or a hydroxyl protecting group, to afford a compound of general formula (IV)

or a salt thereof;

d) reducing with a source of hydrogen in the presence of a noble metal catalyst and treating with fluoride ion; and

e) if desired, forming a pharmaceutically acceptable acid addition salt.

4. A process according to claim 3 wherein the trialkylsilyl is TBDMS.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 3, 2013
From: ABOLIN, CRAIG R.; WILKINSON, H. SCOTT; MCGLYNN, PAUL; MCVICAR, WILLIAM K.
To: SUNOVION PHARMACEUTICALS, INC.
Reel/Frame 030737/0934 →
Continuity (3)
Continuation 12196520 · Aug 22, 2008
Provisional Application 60966438 · Aug 28, 2007
Related Publication 20130296607A1 · Nov 7, 2013